Propella
Global life sciences company headquartered in Tokyo with R&D, manufacturing and commercialization operations across oncology, ophthalmology, urology, immunology and women’s health. Active in drug discovery and platform R&D (including gene and cell therapy), global manufacturing and supply chain operations, digital health and AI analytics, and external partnering and open innovation. Publishes country-level transparency disclosures and maintains patient centricity programs to integrate patient insights into R&D and development.
Industries
Nr. of Employees
small (1-50)
Propella
Headquarters: Tokyo, Japan. Global offices and manufacturing sites listed on corporate website.
Products
PADCEV (enfortumab vedotin)
Antibody-drug conjugate for treatment of locally advanced or metastatic urothelial cancer.
IZERVAY (avacincaptad pegol intravitreal solution)
Intravitreal therapy for geographic atrophy secondary to age-related macular degeneration.
VEOZAH / VEOZA (fezolinetant)
Oral therapy for moderate to severe vasomotor symptoms associated with menopause.
VYLOY (zolbetuximab)
Monoclonal antibody for first-line treatment of CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma.
XOSPATA (gilteritinib)
Oral therapy for relapsed or refractory acute myeloid leukemia with FLT3 mutation.
XTANDI (enzalutamide)
Oral androgen receptor inhibitor used for various forms of advanced prostate cancer.
PADCEV (enfortumab vedotin)
Antibody-drug conjugate for treatment of locally advanced or metastatic urothelial cancer.
IZERVAY (avacincaptad pegol intravitreal solution)
Intravitreal therapy for geographic atrophy secondary to age-related macular degeneration.
VEOZAH / VEOZA (fezolinetant)
Oral therapy for moderate to severe vasomotor symptoms associated with menopause.
VYLOY (zolbetuximab)
Monoclonal antibody for first-line treatment of CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma.
XOSPATA (gilteritinib)
Oral therapy for relapsed or refractory acute myeloid leukemia with FLT3 mutation.
XTANDI (enzalutamide)
Oral androgen receptor inhibitor used for various forms of advanced prostate cancer.
Services
Grants and investigator-sponsored research (ISR) support for independent scientific initiatives.
Research collaborations, licensing, option agreements and M&A to co-develop and commercialize therapeutics and platforms.
Programs to develop and scale digital health solutions complementary to therapeutic portfolios and chronic disease management.
Publication and distribution of EFPIA and national disclosure reports, methodology notes and patient organisation reports for specific countries; reports are available for download per country (examples include Italy, Netherlands, Sweden, Switzerland and others).
Organized patient partnership, medical intelligence and patient insights activities to incorporate patient experience into R&D and product development.
Grants and investigator-sponsored research (ISR) support for independent scientific initiatives.
Research collaborations, licensing, option agreements and M&A to co-develop and commercialize therapeutics and platforms.
Programs to develop and scale digital health solutions complementary to therapeutic portfolios and chronic disease management.
Publication and distribution of EFPIA and national disclosure reports, methodology notes and patient organisation reports for specific countries; reports are available for download per country (examples include Italy, Netherlands, Sweden, Switzerland and others).
Organized patient partnership, medical intelligence and patient insights activities to incorporate patient experience into R&D and product development.
Expertise Areas
- Clinical trial management
- Real-world evidence and patient-centric outcomes
- Drug discovery and platform R&D
- Cell and gene therapy development
Key Technologies
- AAV vector engineering
- Cell and gene therapy manufacturing
- Targeted protein degradation modalities
- Bispecific and T-cell engager antibodies
News & Updates
Published financial results for Q2 year-to-date FY2025.
Annual integrated report providing stakeholder information on strategy, performance and governance.
Annual report detailing patient centricity activities and patient engagement initiatives.
Company celebrated its 20th anniversary in April 2025, marking two decades since the 2005 merger that formed the current organization.
Established a global gene therapy center of excellence to centralize and advance gene therapy programs.
Annual report documenting patient partnership, medical intelligence and behavioral science activities to integrate patient perspectives across the organization.
Published financial results for Q2 year-to-date FY2025.
Annual integrated report providing stakeholder information on strategy, performance and governance.
Annual report detailing patient centricity activities and patient engagement initiatives.
Company celebrated its 20th anniversary in April 2025, marking two decades since the 2005 merger that formed the current organization.
Established a global gene therapy center of excellence to centralize and advance gene therapy programs.
Annual report documenting patient partnership, medical intelligence and behavioral science activities to integrate patient perspectives across the organization.